WO2022153161 - TREATMENT OF CANCER USING A PRMT5 INHIBITOR
National phase entry is expected:
Publication Number
WO/2022/153161
Publication Date
21.07.2022
International Application No.
PCT/IB2022/050154
International Filing Date
10.01.2022
Title **
[English]
TREATMENT OF CANCER USING A PRMT5 INHIBITOR
[French]
TRAITEMENT DU CANCER À L'AIDE D'UN INHIBITEUR DE PRMT5
Applicants **
PFIZER INC.
Inventors
JENSEN-PERGAKES, Kristen Lee
WANG, Yuli
XIE, Tao
Priority Data
63/137,410
14.01.2021
US
63/289,106
13.12.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2504 | |
| EPO | Filing, Examination, Granting | 12026 | |
| Japan | Filing, Examination, Granting | 2353 | |
| South Korea | Filing, Examination, Granting | 2359 | |
| USA | Filing, Examination, Granting | 5940 |
Total:
25,182
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Abstract[English]
The present disclosure describes methods of treating cancer in a subject having a splicing factor mutation comprising administering to the subject in need thereof a therapeutically effective amount of a S-adenosylmethionine (SAM)-competitive Protein Arginine Methyltransferase 5 (PRMT5) inhibitor.[French]
La présente divulgation concerne des procédés de traitement du cancer chez un sujet ayant une mutation de facteur d'épissage, comprenant l'administration au sujet en ayant besoin d'une quantité thérapeutiquement efficace d'un inhibiteur de la protéine arginine méthyltransférase 5 (PRMT5) S-adénosylméthionine (SAM)-compétitif.